

Index

- absence epilepsies, 181–9
 acquired epilepsy
 acute and remote symptomatic seizures in, 18
 and Alzheimer's disease, 26
 and brain tumors, 23–4
 imaging biomarker evidence for, 18–19
 and multiple sclerosis, 24–5
 and stroke, 19–21
 and TBI, 21–2
 acute symptomatic seizures, 18, 21
 advanced diffusion MRI, 12–13
 AED (antiepileptic drugs)
 and children, 32
 and depression, 208–9
 neuroimaging of, 148–53
 resistance to, 157–65
 targets, 152
 topiramate, 159–61
 zonisamide, 159–61
 Alzheimer's disease, 25–6
 AMT-PET (amitriptyline-positron emission tomography)
 in surgical intervention, 172
 and tryptophan metabolism, 102–4
 anatomical imaging (MRI), 10
 animal studies
 biomarker use for status epilepticus, 5–6
 depression and, 209
 of drug resistance in epilepsy, 148–9
 epileptogenesis prevention, 135–43
 interictal and peri-ictal changes in epilepsy, 108–9
 neural excitability in epilepsy models, 181–9
 neuroinflammation in, 100–1
 PET mapping of epileptogenesis, 95–7
 and posttraumatic epilepsy MRI studies, 9–10
 SPECT imaging, 121
 status epilepticus neuroimaging, 4–5
 arterial spin labeling, 15
 ATLR (anterior temporal lobe resection), 229, 235–6
 autobiographical memory, 234
 basal ganglia, 128–9
 BECTS (benign epilepsy with centrotemporal spikes)
 cognitive performance of, 39–40
 and new onset epilepsy in children, 33–4, 36
 benign mesial temporal epilepsy, 48–53
 biomarkers. *See also* neuroimaging
 of acquired epilepsy, 19
 for AED resistance, 157–65
 and brain tumors, 23–4
 contrast agents, 13
 in status epilepticus neuroimaging, 5–6
 for stroke, 19–21
 surgical interventions in focal epilepsy, 169–76
 for TBI, 16, 22
 blood-brain barrier
 as multidrug transporter, 161
 and TBI, 15, 22
 BOLD (blood-oxygen-level-dependent)
 in functional MRI cognitive tests, 230
 in functional MRI dynamic response, 184–5
 in functional MRI surgical intervention, 173–4
 and language development, 198–9
 brain connectivity
 abnormalities, 111–12
 interictal and peri-ictal changes in epilepsy, 108–12
 and interictal functional MRI, 186–8
 and white matter, 73
 brain development
 control data for, 193
 metabolism and blood flow, 193
 structural imaging of, 194–6
 brain injury
 posttraumatic
 anatomical imaging, 10
 diffusion MRI, 12–13
 functional MRI, 13–15
 future perspectives on, 15–16
 QSM, 10–12
 relaxometry, 10
 and seizure blood supply, 3
 and seizure medicine timing, 1
 brain metabolism mapping, 95–104
 brain tumors, 23–4
 carbamazepine, 158
 cerebellum, 129
 cerebral blood flow
 contrast agents for, 13
 and interictal functional MRI, 187–8
 cerebral blood volume
 contrast agents for, 13
 functional MRI excitability, 186
 and interictal functional MRI, 187–8
 child studies
 biomarker use for status epilepticus, 5–6
 brain development in, 193–201
 epilepsy types in
 absence, 181–9
 BECTS, 33–4, 36, 39–40
 focal, 41–2
 JME, 40
 and epileptogenesis, 1–2
 hippocampal changes during convulsive status epilepticus, 3
 imaging brain metabolism and, 97–8
 language development, 200
 new onset epilepsies in, 31–44
 status epilepticus neuroimaging, 3–4
 cognition
 and DTI, 70–1
 functional MRI to measure, 229–40
 and neural excitability in brain development, 193–201
 and new onset epilepsy in children, 32–5, 36–8
 common brain networks, 110
 computer-aided analysis, 55–64
 convulsive status epilepticus, 3
 cortex, 181–9
 cortical dysplasia
 computational imaging of, 61
 surgical intervention in, 170
 cortical excitability, 182–3
 CT scans, 22
 cytotoxic edema, 12–13

Index

- depression, 207–13
 diffusion MRI
 in epilepsy progression, 217
 and temporal lobes, 128
 and white matter damage, 12–13
 diffusion tensor imaging
 and absence epilepsy, 183–4
 of brain development, 195
 epileptogenesis prevention using, 139
 in focal epilepsy surgical interventions, 170–1
 in generalized epilepsy, 141–2
 for imaging white matter, 68–71
 limitations of, 71–2
 and network disturbances in FLE, 82
 parameters, 13
 relation to cognition, 70–1
 diffusion weighted imaging
 epileptogenesis prevention using, 139
 and interictal MRI, 186–7
 DMN (default mode network)
 and bilateral function, 81
 functional MRI and, 157
 functional MRI studies, 84
 thalamocortical circuitry imaging, 125–6
 drugs. *See* AED
 EEG (electroencephalography). *See also* functional MRI
 for epilepsy network modeling, 78–86
 in focal epilepsy surgical interventions, 174–6
 and functional activity and connectivity in children, 201
 functional MRI in surgical intervention, 173–4
 and neural excitability in epilepsy models, 181–9
 thalamocortical circuitry imaging, 124–31
 electroconvulsive therapy (ECT), 120
 encephalitis, 101–2
 endophenotype, 49
 epilepsy models, 77–86
 epilepsy progression
 neuroimaging studies
 in IGE, 222
 MRI importance in, 217–19
 in TLE, 219–21
 epilepsy types
 benign mesial temporal, 48–53
 intractable, 98–9
 epileptogenesis
 animal prevention studies, 135–43
 and PET mapping, 95–104
 and status epilepticus, 1–2
 and IGE, 83–5
 to measure cognition in epilepsy, 229–40
 and stroke, 21
 of SWD dynamic response, 184–8
 task-based
 language development, 198–9
 working memory, 199
 technical challenges of, 238–9
 thalamus imaging, 124
 and TLE, 77–86
 and TSC, 24
 versus structural MRI, 201
 gadolinium chelate contrast
 agents, 13
 generalized epilepsy
 epileptogenesis prevention imaging for, 139–42
 GGE, 124–31
 IGE, 63–4, 77, 83–5
 genetic hypothesis, 161
 genetics
 of benign mesial temporal epilepsy, 48–53
 influence on functional MRI, 129–31
 GGE (genetic generalized epilepsies), 124–31
 glucose metabolism
 in clinical epilepsy, 98–9
 and PET mapping of epileptogenesis, 95–7
 graph theory, 78
 hemorrhage
 intracerebral, 20
 and magnetic susceptibility imaging, 10–12
 high field MRI, 5
 hippocampus
 and ATR memory changes, 235–6
 in benign mesial temporal epilepsy, 50–2
 in convulsive status epilepticus, 3
 growth in children, 6
 language functions of, 232
 main pathophysiological processes following status epilepticus, 4–5
 in predicting surgical outcomes, 169
 sclerosis, 22
 and status epilepticus, 1–2
 hypometabolism, 95–9
 IGE (idiopathic generalized epilepsies)
 computational imaging
 of, 63–4
 and epilepsy progression, 222
 as network disorder, 77, 83–5
 valproate response, 159
 episodic memory, 234–5
 excitability (neural)
 and cognition in brain development, 193–201
 and the origin of SWDs, 182–3
 SWD, 186
 toxicity, 4
 extratemporal refractory epilepsy
 EEG in surgical interventions, 175–6
 MEG in surgical interventions, 176
 PET imaging in surgical intervention, 172
 surgical intervention using functional MRI, 174
 FCD (focal cortical dysplasia)
 computational imaging of, 59–61
 diffusion tensor imaging for, 70
 FDG-PET (fluorodeoxyglucose)
 and brain development studies, 193
 and decreased glucose metabolism, 221
 glucose metabolism in, 98–9
 in surgical intervention, 171–2
 febrile seizures, 135–6
 fixel-based analysis, 72
 FLAIR (fluid attenuated inversion recovery)
 computational analysis, 56
 coronal, 52, 196, 218
 in FCD Type II lesions, 59, 61
 midtemporal, 104
 and multiple sclerosis, 25
 FLE (frontal lobe epilepsy)
 evidence for network disturbances in, 234
 memory changes after surgery, 237
 thalamocortical circuitry imaging, 126–8
 flumazenil, 172
 focal epilepsies. *See also* TLE
 computational imaging of, 59–61
 imaging white matter in, 68–73
 network changes in, 108–12
 and new onset epilepsy in children, 41–2
 surgical interventions using imaging biomarkers, 169–76
 frontal cortex, 182–3
 functional MRI. *See also* SPECT
 imaging, MRI, EEG
 for AED resistance, 157–61
 and epilepsy as a network disorder, 78
 for epileptogenesis prevention, 138–9
 in focal epilepsy surgical interventions, 173–4
 for generalized epilepsy, 140–1
 genetic factors influence on, 129–31

- inflammation
 mapping, 95–104
 and status epilepticus, 5
 intelligence. *See* cognition
 interictal network
 changes in focal epilepsy, 108–12
 SPECT imaging, 116–17
 surgical techniques for, 172–3
 intracarotid amytal test (IAT), 229, 232
 intractable epilepsies, 98–9
 intrinsic severity hypothesis, 161
- JME (juvenile myoclonic epilepsy)
 genetic factors influence on, 129–31
 and IGE, 83–5
 and new onset epilepsy in children, 40
 thalamocortical circuitry imaging, 126–8
 valproate response, 159
- language development
 functional imaging of, 198–9
 functional MRI assessment, 230–4
 studies, 200
- levetiracetam
 and depression, 213
 functional MRI and, 159
 longitudinal studies, 218–19
- magnetization transfer imaging, 22
 manganese-enhanced MRI, 5
 material specific memory, 234–5
 mean transit time, 13
 medial temporal lobe, 234–5
 MEG (magnetoencephalography), 77, 176
- memory impairment
 autobiographical, 234
 material specificity and episodic, 234–5
 postoperative changes in, 235–6
 working, 236–8
- metabolism
 and brain development, 194
 and depression, 209
 glucose, 95–9
 mapping, 95–104
 microglia, 101–2
- morbidity
 and abnormalities in TLE, 58–9
 epilepsy and depression, 207–13
 and new onset epilepsy, 32
 and status epilepticus, 1
- MRI (magnetic resonance imaging).
See also neuroimaging
 in animal PFS, 4–5
 benign mesial temporal epilepsy, 48–53
 child TLE-MTS, 2–4
 and computational neuroimaging of epilepsy, 55–64
 computer models of network disorders, 77–86
 and epilepsy progression, 217–18
 and epileptogenesis, 1–2
 epileptogenesis prevention, 135–7
 focal epilepsy surgical interventions, 169–70
 imaging thalamocortical circuitry, 124–31
 and PET glucose metabolism, 207–13
 and posttraumatic epilepsy, 9–16
 and status epilepticus, 1
 structural, 183–4
 and TBI, 22
- MRS (magnetic resonance spectroscopy)
 for AED resistance, 157
 and TLE, 171
- MTS (mesial temporal sclerosis)
 and brain development studies, 196
 and convulsive status epilepticus, 3–4
 and depression, 208, 209
 and epileptogenesis, 1–2
 extrahippocampal changes, 4
 multiple sclerosis, 24–5
- near-infrared spectroscopy, 186
- network analysis
 in focal epilepsy, 108–12
 relevance of for epilepsy
 SPECT imaging, 119–21
 network hypothesis, 161
 neural disorder (epilepsy as), 77–86
 neurocysticercosis, 102
 neuroimaging. *See also* MRI,
 functional MRI, biomarkers
 absence epilepsies, 183–4
 for benign mesial temporal epilepsy, 48–53
- brain network changes in epilepsy, 108–12
 depression changes in, 210–12
 epilepsy computational analysis, 55–64
 of epilepsy drug resistance, 148–53
 of epilepsy progression, 217–24
 mapping metabolism and inflammation in epilepsy, 95–104
 and new onset epilepsy in children, 35–6, 39
 SPECT, 115–22
- neuroinflammation. *See* inflammation
 new onset epilepsies, 31–44
- NODDI (neurite orientation dispersion and density imaging), 72–3
- oxcarbazepine, 158
- partial epilepsies, 135–7
- peri-ictal network
 in focal epilepsy, 109–10
 SPECT imaging, 108–12, 115–16
- PET (positron emission tomography)
 and depression, 207–13
 [11C]-N-desmethyl-loperamide, 163
 of epilepsy drug resistance, 151–3
 epileptogenesis prevention using, 137–8
 in focal epilepsy surgical interventions, 171–2
 mapping for metabolism and inflammation, 95–104
 Pgp tracers, 164
 radiolabeled antiepileptic drug, 163
 and tuberous sclerosis complex, 24
 [11C]verapamil, 161–3
- PFS (prolonged febrile seizures)
 in animals, 4–5
 hippocampal injury in, 2, 3
- P-glycoprotein (Pgp), 161–4
 postoperative memory impairment, 235–6
- posttraumatic brain injury
 advanced diffusion MRI, 12–13
 anatomical imaging, 10
 functional MRI, 13–15
 future perspectives on, 15–16
 quantitative susceptibility mapping, 10–12
 relaxation mapping, 10
 posttraumatic epilepsy, 136
- proton magnetic resonance spectroscopy (PMRS)
 for AED resistance, 157
 epileptogenesis prevention using, 137
- QSM (quantitative susceptibility mapping), 10–12
- radio-isotope imaging
 and brain development studies, 193
 of epilepsy drug resistance, 148–53
- recent-onset epilepsy, 98–9
 relaxation along fictitious field (RAFF), 16
 relaxation time mapping, 10
 remote symptomatic seizures, 18
- serotonin
 and depression, 212–13
 and epilepsy, 209

Index

- 5HT1A receptor (serotonin 1A receptor), 210–12
- 5HTT receptor (serotonin transporter gene), 212–13
- SISCOM (subtraction ictal SPECT coregistered to MRI), 116, 117–18, 173
- SPECT imaging (single photon emission computed tomography). *See also* functional MRI, biomarkers and brain development studies, 193 as biomarker of epileptic seizures, 115 as marker of seizure-onset zone combined with other functional imaging, 119 interictal, 116–17 SISCOM, 117–18 SPM-based subtraction, 118–19 by visual inspection, 117 ictal techniques peri-ictal dynamics, 115–16 SISCOM, 116 SPM-based subtraction, 116 in focal epilepsy surgical interventions, 172–3 role in evaluating epileptic networks, 119–21
- SPM (statistical parameter mapping), 116, 118–19
- status epilepticus defined, 1 importance of epileptogenesis, 1–2 mortality, 1
- status epilepticus neuroimaging animal studies, 4–5, 137 and biomarker use, 5–6 child studies extrahippocampal changes, 4 hippocampal changes, 3 image markers of glucose metabolism, 95–7 as noninvasive biomarker, 2 stroke and epilepsy epidemiology of, 19 imaging biomarker evidence for, 19–21 imaging brain metabolism and, 97–8 structural MRI and absence epilepsy, 183–4 of brain development, 194–6 versus functional MRI, 201 and working memory, 199
- Sturge-Weber syndrome (SWS), 97–8
- surface-based methods of computational imaging, 60–1 for white matter, 70
- Surfpatch, 56–7
- susceptibility weighted imaging (SWI) and brain tumors, 24 and TBI, 22
- SWD (spike wave discharges) functional MRI of dynamic responses, 184–8 thalamus versus cortex, 181–9 using DTI, 183–4 using structural MRI, 184
- system epilepsies, 77
- target hypothesis, 161
- TBI (traumatic brain injury) and acquired epilepsy, 21–2 experimental MRI and, 9–16 MRI for posttraumatic epilepsy, 136 and PET mapping of epileptogenesis, 96
- thalamocortical circuitry imaging basal ganglia, 128–9 cerebellum, 129 default mode network, 125–6 frontal lobes, 126–8 influence of genetic factors on, 129–31 temporal lobes, 128–9 thalamus, 124
- thalamus, 181–9
- TLE (temporal lobe epilepsy). *See also* focal epilepsies and AED resistance, 157 brain networks associated with, 120–1 cognitive effects in, 229 and depression, 208, 212–13 diffusion lobe abnormalities in, 69 EEG in surgical interventions, 174 and epileptogenesis, 1–2 extrahippocampal changes, 4 language functions in, 233 MEG in surgical interventions, 176 memory changes after surgery, 234–8 MRI imaging in surgical intervention, 169–70 MRI studies of, 77–86
- MRS imaging in surgical intervention, 171
- MTS, 2–4, 5–6 as a network disorder, 80–2
- PET imaging in surgical intervention, 171–2 progression of, 219–21
- STATISCOM in surgical interventions, 173
- surgical intervention using functional MRI, 173–4
- thalamocortical circuitry imaging, 128–9 voxel-based morphometry for, 68
- topiramate and depression, 213 functional MRI and, 159–61
- transcranial magnetic stimulation, 158–9
- transporter expression, 149–52 hypothesis, 161, 165
- tryptophan metabolism, 102–4
- TSC (tuberous sclerosis complex) imaging brain metabolism and, 97–8 PET imaging in surgical intervention, 172 types of imaging for, 24
- valproate, 158–9 [11C]verapamil, 161–3
- vigabatrin, 207
- voxel-based morphometry for AED resistance, 157 in benign mesial temporal epilepsy, 52 and depression, 208 of epilepsy progression, 221 of focal epilepsy, 60 for generalized epilepsy, 140 for imaging white matter, 68 for surgical intervention in TLE, 170
- white matter (brain) in brain development, 195–6 differences in epilepsies, 200 fiber tractography, 139 imaging technologies for, 68–73 working memory, 198–9, 200, 236–8
- zonisamide and depression, 207 functional MRI and, 159–61